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Abstract
Pregnant women and their unborn children are vulnerable to malaria increasing the risk of
maternal anaemia, low birth weight (LBW) and intrauterine growth retardation. There is little
evidence on the cost-effectiveness of intermittent preventive treatment in pregnancy (IPTp) and
insecticide-treated bed nets (ITNs) in areas of low transmission.
A randomised controlled trial with three arms was conducted in antenatal clinics in Kabale
District, Uganda, an epidemic-prone highland area of low malaria transmission. The interventions
were (i) IPTp with sulphadoxine/pyrimethamine (SP) given twice during pregnancy (IPTp-SP);
(ii) ITNs alone; and (iii) a combined intervention with both ITNs and IPTp-SP. Primary health
outcomes were LBW and maternal anaemia. The costs of providing IPTp-SP and ITNs as well as
treatment of malaria episodes were captured from all health centres in the study area.
There were no significant differences in health outcomes among the three interventions. The cost-
effectiveness analysis and sensitivity analyses performed did not provide convincing support for
replacing IPTp-SP (current policy) by ITNs alone or by a combined intervention in this low
transmission setting on economic grounds. The cost per pregnant woman of providing the services
was lowest for the IPTp-SP intervention (US$0.79 per woman) followed by ITNs (US$1.71) and
the combined intervention of IPTp-SP + ITNs (US$2.48). The relative cost-effectiveness of
antenatal distribution of ITNs might improve if the cost savings accruing from continued use of a
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long-lasting insecticidal net after pregnancy as well as positive externalities were also taken into
account, and this warrants further study.
Keywords
malaria prevention; pregnancy; intermittent preventive treatment; insecticide-treated nets; cost-
effectiveness analysis; low transmission; highlands
Introduction
According to recent estimates, more than 8 million people in Africa and 985 million people
globally were living in areas with unstable P. falciparum malaria transmission in 2007.1
Further, an estimated number of 0.4 million pregnancies in Africa and 30.6 million
pregnancies globally were at risk of P. falciparum malaria in areas of unstable transmission
in 2007.1 Pregnant women are particularly vulnerable to malaria with adverse consequences
to the mother and unborn child such as maternal anaemia, low birth weight (LBW) and
intrauterine growth retardation.2 Fortunately, a number of efficacious and cost-effective
interventions exist to prevent malaria in pregnancy, however evidence of their cost-
effectiveness in areas of low transmission areas is lacking.
Intermittent preventive treatment in pregnancy (IPTp) using a full dose of sulphadoxine/
pyrimethamine (SP) two or more times during pregnancy has been shown to be effective in
increasing mean birthweight and reducing the frequency of LBW babies.3 Studies have
shown IPTp with SP (IPTp-SP) to be a very cost-effective health intervention. Goodman et
al4 estimated the cost per disability-adjusted life year (DALY) averted to the public
healthcare sector of this intervention to be US$12 if provided for primigravidae only and US
$32 if provided for all pregnancies in a low income country. Furthermore, Wolfe et al5
estimated the health sector cost per DALY averted in the range of US$11-14 depending on
the number of doses of SP and HIV prevalence. Mbonye et al6 found that the incremental
cost per DALY averted for community-based delivery of IPTp-SP provided by traditional
birth attendants, drug vendors, community health workers and adolescent peer mobilisers
was just above US$1 compared with facility-based IPTp-SP in Uganda. Current World
Health Organization (WHO) guidelines recommend IPTp with at least two doses of
treatment in areas of medium or high transmission, whilst there is insufficient evidence to
recommend IPTp in low and unstable transmission areas.7
Insecticide-treated nets (ITNs) may reduce the number of malaria infections and LBW
babies as compared to not sleeping under a net during pregnancy.8 Whilst ITNs have been
found to be a very cost-effective health intervention for children below 5 years,9,10 the
benefits and cost-effectiveness among pregnant women are less well documented,11
especially in areas of low malaria transmission.12 The current WHO policy guidance for
sub-Saharan Africa recommends the use of both IPTp and ITNs for the prevention of
malaria during pregnancy in areas of stable transmission,7 but there are no specific
recommendations for areas of low and unstable transmission.
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There is little evidence on the impact and cost-effectiveness of the combined utilisation of
IPTp and ITNs for the prevention of malaria in pregnancy in Africa, particularly in areas of
low transmission.13 Njagi et al14 demonstrated a significant protective effect of combined
ITNs and IPTp on anaemia in primigravidae, as well as a protective effect of ITNs alone, in
an area of intense perennial transmission in western Kenya. Menendez et al15,16 found no
additional effect of IPTp on LBW but significant reductions in clinical malaria during
pregnancy and in neonatal mortality in a placebo-controlled trial in Mozambique where all
women also received an ITN. The cost-effectiveness component of the same study estimated
that the incremental cost of IPTp per DALY averted was US$1 when reductions in both
maternal malaria and neonatal malaria were included in the analysis.17 The incremental cost
per DALY averted was estimated to be US$17 when adding a bed net distribution
programme to IPTp-SP in the Democratic Republic of Congo.18
We therefore conducted a randomised controlled trial and cost-effectiveness analysis in a
low and unstable transmission area of Uganda with the objective of comparing current
national policy of IPTp-SP with either ITNs alone, or with IPTp-SP given in combination
with ITNs. The design of the trial and impact of the interventions on maternal and birth
outcomes are reported elsewhere.19 Here, we present the results of the cost-effectiveness
analysis.
Methodology
Study site and population
The study was conducted in Kabale district in south-western Uganda, situated at an altitude
between 1219m and 2347m above sea level. The majority of the district lies within the
malaria epidemic-prone zone, between 1440m and 2200m above sea level and the
temperature is fairly constant throughout the year, with maximum daily temperatures of
23.2-24.4 °C. Rainfall is seasonally bimodal, averaging between 1000 and 1480 mm per
annum. Malaria transmission is low and unstable but occurs most years, and usually peaks
during April-June and September-November following rainfall. The intensity and extent of
transmission varies from year to year, resulting in periodic epidemics which are associated
with high morbidity and mortality rates, and an increase in stillbirths.20 The study area was
limited to the lowest lying sub-counties of the district at greatest risk of malaria
transmission.
Interventions
The current national policy in Uganda for prevention of malaria in pregnancy is IPTp-SP
given twice during pregnancy [first dose in the second trimester, after quickening, and the
second dose in the third trimester (gestational weeks 28-34)]. IPTp-SP is delivered as part of
the standard antenatal care (ANC) services offered at health centres and hospitals. During
ANC visits nurses will explain the benefits of IPTp to pregnant women and administer SP
under direct observation.
The second intervention was ITNs without IPTp. Whilst this service was not routinely
offered in the Ugandan public healthcare sector, the clinics participating in the trial
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delivered bed nets treated with KO-tab® deltametrin as part of standard ANC services.
Pregnant women received a bed net at first ANC visit where proper use of the net was
explained by nurses/midwives. Impregnation was done by health facility personnel prior to
distribution.
The third intervention was a combination of both ITNs and IPTp-SP.
Study design
Pregnant women presenting at <27 weeks gestation at first ANC visit to rural health
facilities, staffed with at least one midwife offering ANC services, were recruited into the
study (see Ndyomugyenyi et al19 for more details). Exclusion criteria included: severe
anaemia at time of antenatal booking; current or past severe disease; and residence outside
the study area. After written informed consent was obtained, women were randomised to
one of the above-described interventions. Women were followed until 1 month after delivery
(abortion or birth of child) resulting in a follow-up period of 5 months on average. The
sample size for this superiority trial was determined to detect a 50% reduction in the
prevalence of LBW (<2500 g) among babies born under current practice compared to the
two new interventions. The birth of a LBW baby was the least common health outcome and
assuming a significance level of 0.05 and power of 0.80, this resulted in a sample size of
1604 women per arm. Pregnant women were recruited over a period of three years from
2004 to 2007 whilst the required unit cost data were collected for the financial year 2004/05.
Measurement of health outcomes by study arm
Main health outcomes were the number og LBW babies and the prevalence of maternal
anaemia at 36-40 weeks gestation among enrolled women. As part of the efficacy trial
component of this study, a total of 1798, 1778 and 1752 pregnant women in each study arm
respectively were followed over an average of 5 months until delivery to capture health
outcomes (see Ndyomugyenyi et al19 for details). Health outcomes were transformed into
DALYs lost.21 The (untreated) disability weight for LBW and the associated disabilities was
0.291,21 whilst the life expectancies of a male and female newborn baby in Uganda in 2002
were 48.8 and 52.0 years, respectively.22 Using an average life expectancy of 50.4 years for
both sexes and the remaining value choices of the DALY including the age weighting
function and a discount rate of 3% for future life years,21 this resulted in 8.61 DALYs lost
per LBW baby. Similarly, it was calculated that an episode of maternal anaemia meant a loss
of 0.0015 DALYs based on an assumption that each episode lasted on average 1 month with
a disability weight of 0.012.21 Total DALYs lost were calculated for a reference population
of 1000 women in each study arm by multiplying DALYs lost per LBW baby and per
maternal anaemia episode by the number of adverse health outcomes for the reference
populations using the prevalences found in the efficacy component of this study.19
Collection and measurement of costs by study arm
Costs were collected from a provider’s perspective meaning that only costs borne by the
public healthcare sector were included. Economic rather than financial costs were collected.
IPTp delivered as part of public sector ANC is free. It was also assumed that the distribution
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of ITNs at ANC would be free so the full costs of these interventions were therefore
assumed to be borne by the public healthcare sector.
Intervention costs consisted of the costs of administering SP during ANC visits at health
centres and the costs of impregnating nets and distributing these from health centres. Cost
savings might arise if an intervention reduces the number of malaria episodes during
pregnancy leading to fewer outpatient visits for malaria treatment. The unit costs per service
for administering SP during ANC, impregnation and distribution of ITNs and outpatient
treatment for malaria were estimated based on cost data collected from all health centres
situated in the study area. There were seven health centres within the study area of which
five were recruiting women into the trial when the cost data were collected in 2005.
Collection of cost data at health centres was guided by a combination of the standard step-
down costing methodology23,24 and micro-costing,25 as described in more detail below.
Information on overall level of recurrent expenditure by category (drugs, stationery, utilities,
etc) for the 2004/05 financial year for the study health centres was obtained from the
accountant at the District Director of Health Services’ Office in Kabale. A list of staff, job
title and grade was compiled during field visits and the annual salary including allowances
by type of personnel was calculated using the government salary scale. Capital inputs at
health centres were buildings, equipment and furniture. The size (in m2) of health centres
was approximated using plans of standard health centres available from Ministry of Health
and information on construction cost per m2 for such buildings was captured from a public
sector quantity surveyor. An inventory of equipment and furniture was developed during the
field visit at each health centre and these items were subsequently valued using a relevant
price list26 and a price survey conducted in Kampala. Annual equivalents23 of these capital
costs were calculated using a discount rate of 3% and expected life spans of buildings,
equipment and furniture of 30, 7 and 10 years, respectively.
The total recurrent and capital costs at health centre level were in the first step of the
standard step-down costing23,24 distributed to the relevant cost centres including overhead
activities (administration), support activities (pharmacy, laboratory) and final services (ANC
visits, vaccinations, outpatient visits, etc) using relevant allocation criteria expected to
reflect actual resource utilisation. The second and third steps of the step-down costing
consisted of allocating the costs of overhead and support activities respectively to individual
final services including ANC visits with SP, impregnation and distribution of ITNs, and
outpatient visits for malaria treatment. Allocation criteria for the three steps were developed
during the data collection visits. For instance, salary costs were allocated to main activities
following interviews with staff who estimated how much time was spent on each type of
service e.g. 15 minutes per outpatient visit, 15 minutes to distribute and explain the proper
usage of an ITN, 20 minutes for impregnating a net and 15 minutes per ANC visit of which
20% or 3 minutes were dedicated to administering SP. As another example of an allocation
criterion, building costs of different rooms were allocated according to the purpose of the
room i.e. the pharmacy was allocated to pharmacy services. With respect to SP tablets, bed
nets, insecticide used per bed net, malaria drugs given during an outpatient visit and medical
disposables used for these services, interviews with relevant staff and official guidelines27
provided information on utilisation per visit and prices of these commodities were taken
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from a relevant price list.26 At the end of this process, the health centre level costs had been
allocated to final services, and dividing by the number of final services performed in the
financial year 2004/05, the unit cost per individual service at the seven study health centres
was arrived at.
Since administration of SP for IPTp was only one out of several standard activities
performed as part of ANC, only 20% of salary costs and all other non-drug costs of an ANC
visit were allocated to IPTp whilst all costs of SP tablets were included in the IPTp
interventions. The expected lifespan of the bednets was 30 months but only 5/30 (16.7%) of
the costs of these were allocated to the interventions since women typically first attended
ANC during the fourth month of pregnancy and the measurement of health effects was
confined to the 5 month observation period of the pregnancy. Likewise, only 5/30 (16.7%)
of the salary and other health centre costs related to distribution of bednets were allocated to
the interventions. A bednet was interpreted as a capital good and an annual equivalent was
calculated, allocating 5/12 (41.7%) of the annual equivalent to the intervention. The period
over which the impregnation was effective was 12 months so only 5/12 (41.7%) of the
impregnation chemical costs were allocated to the study interventions.
The average of unit costs per service for administering SP during ANC, impregnation and
distribution of ITNs and outpatient treatment for malaria was calculated from the seven
study health centres and used for all subsequent cost calculations. Nurses at the study health
centres captured the numbers of ANC visits with SP, ITNs distributed and outpatient visits
for malaria treatment among all enrolled women, which were used to estimate the number of
services for a reference population of 1000 women in each study arm. Total cost by study
arm was calculated by multiplying these numbers by the average of unit costs.
Incremental cost-effectiveness ratios (ICER)
The total costs and effects measured in DALYs lost for each of the three intervention arms
were used to calculate the incremental costs and incremental effects from replacing the
current practice by each of the new interventions. The ICER of replacing current practice of
IPTp-SP by ITNs only was calculated by subtracting the total cost of the IPTp-SP arm from
the total cost of the ITNs only arm for the numerator and subtracting the total DALYs lost in
the IPTp-SP arm from the total DALYs lost in the ITNs only arm for the denominator
(intervention 2 versus intervention 1). This ratio could then be interpreted as the incremental
cost per DALY averted (incremental effects) if IPTp-SP was replaced by ITNs only. The
incremental cost-effectiveness ratio of adding ITNs to current practice of IPTp-SP
(intervention 3 versus intervention 1) was calculated in the same fashion.
The trial component of this study showed that there were no significant differences in
maternal anaemia and number of LBW babies born in the three intervention arms.19 Since
the trial was not designed as an equivalence trial,28 the evaluation did not proceed as a cost-
minimisation analysis.29 Instead ICERs for the two new interventions were calculated and
sensitivity analyses were used to quantify the uncertainty in incremental cost per
incremental effect as recommended by several authors.30,31
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Sensitivity analyses
Several parameters described above were uncertain so the robustness of the baseline ICERs
was assessed with a range of sensitivity analyses. Probabilistic sensitivity analysis (PSA)32
was used to assess the influence of multivariate uncertainty in health outcomes and cost per
service on the ICER. Health outcome data for individual women in the different study arms
were binomial and the uncertainty was therefore described by beta distributions32 with the
necessary parameters estimated from the trial component of this study19 (Table 1).
Calculation of the cost per service in seven health centres revealed that these varied
considerably, mainly due to differences in volumes of patient attendance (Table 2).
Uncertainty of average cost per service was represented by gamma distributions which are
defined for non-negative values only and skewed to the right. Gamma distributions are
therefore be particularly relevant for cost data.32 Parameters for the gamma distributions
were estimated based on cost per service from the study health centres (Table 2) and shown
in Table 1. The PSA was designed as a Monte Carlo simulation with 10000 iterations using
the @Risk software (Palisade Corporation, New York, USA). Each iteration used randomly
drawn values from the distributions displayed in Table 1 to calculate costs and effects for a
reference population of 1000 individuals in each study arm as well as ICERs of the two new
interventions. The results of the sensitivity analyses were summarised by scatter plots of
joint incremental costs and incremental effects (DALYs averted) and cost-effectiveness
acceptability curves.33
Additional PSAs were repeated with new values for specific variables. First, time utilised
per service was determined by asking health personnel themselves. Separate PSAs were run
assuming that the time utilised by nurses for administering SP could range between 1 minute
and 6 minutes and assuming that time taken to explain the use of bednets ranged between 5
minutes and 30 minutes. Second, the cost implications of distributing a long-lasting
insecticidal net (LLIN) instead of a conventional ITN were investigated as a LLIN would
have no pre-treatment costs to be borne by the public health service. The cost of using
LLINs was explored under a range of assumptions, including a purchase price equal to a
conventional ITN as well as a 30% higher or lower price. The efficacy of a LLIN was
assumed equal to a conventional ITN.19 Third, the cost per service for administration of SP,
distribution of bednets, and outpatient visit for treatment of malaria was recalculated under
the assumptions that attendance to all services offered was up to 10% higher and lower than
the observed level in the seven study health centres.
Ethical approval
The study protocol was approved by the Uganda National Council of Science and
Technology, the Ethical Committee of the London School of Hygiene and Tropical
Medicine, and the Danish National Committee on Biomedical Research Ethics, and
registered on a clinical trials database (www.clinicaltrials.gov: NCT00142207).
Results
Cost per service was captured from all seven health centres in the study area (Table 2).
Average cost per service was used for producing the main results of the cost-effectiveness
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component of the trial in Kabale District (Table 3). The level of maternal anaemia and the
number of LBW babies born in the three intervention arm were not significantly different19
and the number of DALYs lost were therefore also similar. The cost per pregnant woman
covered by IPTp-SP was lowest (US$0.79) compared with ITN alone and the combined
intervention (US$1.71 and US$2.48 per woman respectively). IPTp-SP was therefore the
option with the lowest cost and at the same time having health benefits that were not
significantly different from the other two interventions. The ICERs expressed as the cost per
DALY averted of replacing IPTp-SP by a new intervention were found to be US$54 for
ITNs alone and -US$53 for the combined intervention (Table 3).
The result of the PSA comparing ITNs only with IPTp-SP is presented in Figure 1, showing
pairs of incremental costs and incremental effects following each individual iteration of the
Monte-Carlo simulation. The current practice of offering IPTp-SP only is by definition
represented by the origin so that points above the x-axis represent situations where the ITN
intervention had higher cost than the IPTp-SP intervention and the opposite for points below
the x-axis. Similarly, points to the right of the y-axis represented iterations where the ITN
intervention had a better impact on health than the IPTp-SP intervention leading to a
positive number of DALYs averted, while the opposite was the case for points to the left of
y-axis. As shown in Figure 1, the swarm of joint pairs of incremental costs and effects
extends across the y-axis but is situated completely above the x-axis reflecting the findings
that there was no significant difference in health outcomes between the two interventions
and that the ITN intervention had higher cost. The iterations indicated a relatively large
variation in incremental costs and effects of changing policy from IPTp-SP to ITNs and
therefore also a wide range of ICERs. A substantial proportion of the iterations led to a
negative number of DALYs averted (Figure 1, left of the y-axis) meaning that IPTp-SP was
more effective than ITNs and had lower cost so that IPTp-SP was the best option in those
iterations. Figure 2 shows the results of the PSA of comparing the combined intervention of
ITNs + IPTp-SP with IPTp-SP alone. Similar observations can be made from this sensitivity
analysis as is above, except that the swarm of joint pairs of incremental costs and effects lies
further up reflecting the fact that the combined intervention was the most expensive of the
three interventions tested.
The ICER for each pair of incremental costs and effects is given by the slope of a line
connecting a point and the origin in Figures 1 and 2. This characteristic can be used for the
development of cost-effectiveness acceptability curves which measure the share of ICERs
below a given ceiling ratio. If this ceiling ratio is interpreted as the willingness-to-pay
(WTP) for a health improvement of a relevant health policy maker, then a cost-effectiveness
acceptability curve will represent the probability of an intervention being cost-effective at
different levels of WTP.33 ICERs of Figures 1 and 2 may be represented by the cost-
effectiveness acceptability curves shown in Figure 3. There was a 25% probability that
replacing IPTp-SP by ITNs would be a cost-effective use of resources if the WTP for
averting a DALY was US$25 and a probability of 64% of ITNs being cost-effective if the
WTP for averting a DALY was US$150. These two thresholds have often been used to
classify health interventions as being very cost-effective and cost-effective, respectively.34
At a very high WTP of US$500 per DALY averted, the probability of ITNs being cost-
effective was 69%. The probability of the combined intervention being a cost-effective use
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of resources was much lower. For instance, the probability of the combined intervention
being a cost-effective intervention in place of IPTp-SP was only 12% at a high WTP of US
$500.
The additional PSAs to investigate the impact of different time utilisation by health centre
personnel, use of LLINs instead of conventional ITNs and different levels of attendance in
health centres did not give reason to alter the conclusions above, as the cost-effectiveness
acceptability curves did not change markedly (results not shown). The largest impact was
found in the situation where a LLIN was used at a price 30% lower than the price of a
conventional ITN. The probability that this would be a cost-effective use of resources was
68%, 71% and 72% at WTPs of US$25, US$150 and US$500 respectively.
Generally, the PSAs did not provide strong support for spending the extra resources needed
for replacing IPTp-SP by ITNs and in particular not for replacing IPTp-SP by the combined
intervention.
Discussion
The present randomised intervention trial on the impact of ITNs alone and the combined
package of IPTp-SP + ITNs delivered through ANC services found neither intervention to
be superior to IPTp-SP alone (current policy) in preventing adverse maternal and birth
outcomes in an area of low and unstable malaria transmission.19 The cost-effectiveness
analysis and associated sensitivity analyses did not offer strong support for replacing current
policy of IPTp-SP by ITNs alone or a combination of IPTp-SP + ITNs on economic
grounds. The best alternative to current policy was found to be ITNs alone where the
sensitivity analyses suggested that there could be a probability of approximately 64% that
replacing IPTp-SP by ITNs alone would be cost-effective if the WTP of relevant policy-
makers was US$150 (Figure 3). However, even if the WTP of relevant policy-makers was
$500 or above, the probability of ITNs being more cost-effective than IPTp-SP would not
exceed 72%. These findings may help inform the development of guidelines for prevention
of malaria in pregnancy in areas of low and unstable transmission in Uganda as well as in
other African countries.
These conclusions were based on the trial design, measured outcomes and length of the
period of follow-up in this study. These factors present specific limitations for interpretation
of the cost-effectiveness analysis. In particular, the impact of the interventions on women
and newborns over a longer follow-up period beyond the end of pregnancy was not
evaluated, nor was the size of the costs and effects of individuals not directly protected by
interventions investigated. The relevance of these considerations and influence for the
conclusions on the relative cost-effectiveness of the interventions is discussed below. We
discuss the potential influence of compliance and other factors on study findings
elsewhere19 and are confident that these factors did not affect our conclusions. Compliance
to the interventions was high for both IPTp and ITN use, and there was no evidence of
reduced efficacy of IPTp-SP.19 Nonetheless, should coverage, compliance or efficacy of any
of the interventions be reduced under operational conditions, this may affect the relative
cost-effectiveness of the interventions. Similarly, should SP in the future be replaced by a
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more expensive drug, this would also change the relative cost-effectiveness of the
interventions.
The health outcomes available for analysis include only the immediate and direct impacts of
malaria infection during pregnancy, measured at term, principally LBW and maternal
anaemia. Pregnant women were followed for an average period of 5 months so costs and
effects were measured for this period. However, interventions with ITNs in particular would
be expected to have positive health effects in the future over the full lifespan of a bednet.
Though the cost of a net was discounted over the 30 month lifespan during which a
conventional treated net would remain fully efficacious, the possible additional health
effects of sleeping under an ITN after the 5-month follow-up (averted malaria episodes and
maternal deaths) were not captured. Also, the continuing positive health effects to the
newborn child sleeping with the mother under the ITN were not captured as well as averted
malaria episodes in children sleeping with the mother while she was pregnant. Averted
adverse health events would also lead to cost saving both in the healthcare sector and for the
households.
Furthermore, it has been demonstrated that with high coverage, ITNs may offer protection to
individuals not sleeping under a bednet in a household and even people residing in
households without bednets.35-37 These additional benefits are often termed a positive
externality or community effects.9 The extent of a positive externality among individuals not
sleeping under a net may become a relevant issue to explore .37 If distribution of ITNs
contributes to reduced transmission through increasing community coverage of ITNs, this
intervention could have a positive externality. Estimating the size of the costs and effects of
individuals indirectly protected by interventions presents a challenge for calculating the
cost-effectiveness of ITNs. Including possible positive externalities and cost savings
accruing from continued use of a LLIN after pregnancy would likely improve the relative
cost-effectiveness of interventions with ITNs as compared to IPTp-SP.
Finally, there might be additional costs and effects of having a LBW baby in the longer term
not captured in this study. While future adverse health events among LBW babies were in
principle captured through the disability weight developed for the DALY methodology, this
was not the case for the future additional costs. LBW babies would typically suffer more
frequently from adverse medical conditions and disabilities over time thus possibly resulting
in more frequent admissions to hospital. There might also be additional household costs for
families with a LBW baby in terms of purchasing extra medicines, extra health care seeking
and time lost when caring for the baby. Determining such morbidity and associated costs
requires a longer follow-up period of 2-3 years with repeated household visits to record
events such as illness episodes and deaths. Whilst repeated visits to households over an
extended period of time have been applied for measuring malaria morbidity and treatment,38
similar longitudinal studies focusing on household costs in preventive malaria interventions
in pregnancy have not been done. As an alternative to repeated visits by interviewers,
families may instead be trained in keeping diaries of relevant events.39 Finally, future health
benefits and averted costs for a longer period could be included using modelling techniques,
which would require reliable estimates from other studies on the effectiveness of health
interventions. Unfortunately, this was not possible in the context of this study, since there
Hansen et al. Page 10
Int Health. Author manuscript; available in PMC 2014 October 15.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
have only been few studies on the effectiveness of ITNs in low transmission areas in
Africa.12 Designing preventive trials with a longer follow-up of mothers and their newborns
may capture household costs which are not typically measured in cost-effectiveness studies
thus potentially concluding that preventive interventions in pregnancy are more cost-
effective when comprehensive household costs are collected. Nonetheless, including the
long-term costs and effects of malaria on birthweight would probably not change the
conclusions of the cost-effectiveness analysis presented here since there was no significant
difference in the prevalence of LBW babies in the three interventions.
In conclusion, in the absence of any demonstrable difference in efficacy between three
interventions on maternal and foetal outcomes19, our economic evaluation did not provide
any additional evidence on economic grounds for replacing IPTp-SP by ITNs alone or by a
combined intervention in a setting of low and unstable transmission. However, the relative
cost-effectiveness of antenatal distribution of ITNs might improve if the cost savings
accruing from continued use of a LLIN after pregnancy and positive externalities were also
taken into account and warrants further study.
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Figure 1. Scatter plot of incremental costs (US$) and incremental effects [disability-adjusted life
years (DALY) averted] resulting from replacing the intermittent preventive treatment in
pregnancy with sulfadoxine/pyrimethamine (ITPp-SP) intervention by the intervention with
insecticide-treated bednets (ITN) alone in an area of low and unstable malaria transmission,
Kabale District, Uganda (US$1 = UGX1760).
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Figure 2. Scatter plot of incremental costs (US$) and incremental effects [disability-adjusted life
years (DALY) averted] resulting from replacing the intermittent preventive treatment in
pregnancy with sulfadoxine/pyrimethamine (ITPp-SP) intervention by the combined
intervention of IPTp-SP plus insecticide-treated bednets (ITN) in an area of low and unstable
malaria transmission, Kabale District, Uganda (US$1 = UGX1760).
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Figure 3. Cost-effectiveness acceptability curves for replacing intermittent preventive treatment
in pregnancy with sulfadoxine/pyrimethamine (ITPp-SP) (current practice) with (i) insecticide-
treated bednets (ITN) only or (ii) a combined intervention of IPTp-SP plus ITNs, in an area of
low and unstable malaria transmission, Kabale District, Uganda (US$1 = UGX1760). DALY:
disability-adjusted life years.
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Table 1
Input variables and distributions used for the sensitivity analyses of three interventions to
prevent malaria in pregnancy, Kabale District, Uganda (US$1 = UGX1760).
Distribution
Input variable IPTp-SP ITN only IPTp-SP + ITN Source
Health outcomes
Maternal anaemia Beta Beta Beta 19
Episodes α=142 α=163 α=136
β=858 β=837 β=864
Low birth weight Beta Beta Beta 19
Babies α=65 α=63 α=69
β=935 β=937 β=931
Health centre cost per service in US$
Administration of SP during ANC Gamma Gamma Cost data from present study
α=29 α=29
β=0.010 β=0.010
Distribution of ITNs Gamma Gamma Cost data from present study
α=327 α=327
β=0.005 β=0.005
Malaria treatment Gamma Gamma Gamma Cost data from present study
α=42 α=42 α=42
β=0.017 β=0.017 β=0.017
IPTp-SP: intermittent preventive treatment in pregnancy with sulfadoxine/pyrimethamine; ITN: insecticide-treated bednet; ANC: antenatal care
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Table 2
Cost per service in seven health centres in Kabale District, Uganda, for the financial year
2004/05 (US$1 = UGX1760).
Health centre
1 2 3 4 5 6 7
SP administration during ANC
Cost per service (US$) 0.33 0.19 0.34 0.30 0.30 0.26 NA
Distributed across (%):
Salaries 30 28 26 31 27 17 -
Drugs 27 42 26 31 28 38 -
Bednets and insecticides 0 0 0 0 0 0 -
Other recurrent costs 2 1 2 4 3 1 -
Admin, other overhead 10 9 12 12 9 16 -
Capital costs 31 19 35 22 33 26 -
Total 100 100 100 100 100 100 -
Bed net impregnation and distribution
Cost per service (US$) 1.73 1.56 1.72 1.81 1.66 NA NA
Distributed across (%):
Salaries 8 6 7 8 6 - -
Drugs 0 0 0 0 0 - -
Bednets and insecticides 84 90 85 83 86 - -
Other recurrent costs 0 0 0 0 0 - -
Admin, other overhead 4 2 4 4 3 - -
Capital costs 4 2 4 4 4 - -
Total 100 100 100 100 100 - -
Outpatient visit for malaria treatment
Cost per service (US$) 0.69 0.60 0.87 0.87 0.70 0.65 0.62
Distributed across (%):
Salaries 36 45 38 39 42 23 22
Drugs 32 28 25 29 26 33 33
Bednets and insecticides 0 0 0 0 0 0 0
Other recurrent costs 2 1 1 3 2 1 2
Admin, other overhead 8 10 15 13 13 21 17
Capital costs 23 15 20 17 18 21 26
Total 100 100 100 100 100 100 100
SP: sulfadoxine/pyrimethamine; ANC: antenatal care; NA: not available
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Table 3
Costs and effects of three interventions to prevent malaria in pregnancy and incremental
cost-effectiveness ratios (ICER) of new interventions, Kabale District, Uganda (US$1 =
UGX1760).
Intervention
IPTp-SP ITN only IPTp-SP + ITN
Number of pregnant women 1000 1000 1000
Health outcomes
Number of women with maternal anaemia 142 163 136
Number of low birthweight babies 65 63 69
Number of DALYs lost 558 541 590
Number of services
Administration of SP 2680 0 2679
ITN distribution 0 999 1000
Treatment of clinical malaria at health centre 28 26 20
Cost per unit of service (US$) a
Administration of SP 0.3 0.3 0.3
ITN distribution 1.7 1.7 1.7
Treatment of clinical malaria at health centre 0.7 0.7 0.7
Total costs by component (US$)
IPTp component 766 0 766
ITN component 0 1696 1697
Treatment of clinical malaria 20 19 14
Total costs (US$) 786 1715 2477
Cost per pregnant woman (US$) 0.79 1.71 2.48
Incremental costs 929 1691
Incremental effects (DALYs averted) 17 −32
Incremental cost per DALY averted (ICER in US$) 54 −53
IPTp-SP: intermittent preventive treatment in pregnancy with sulfadoxine/pyrimethamine; ITN: insecticide-treated bednet; DALY: disability-
adjusted life year
a
Mean costs among seven health centres in Kabale District, Uganda
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